Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
For more details, click here for the full news release.
Latest Financial Results
Q3 2022
Quarter Ended Sep 30, 2022
Email Alerts
Stay informed and receive company updates straight to your inbox.
Stock Information
Company Overview
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.
Investor Contact Information
Company
Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-681-9815
[email protected]
Investor Relations
LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
[email protected]
CoreIR
377 Oak Street, Level 2
Garden City, New York 11530
T: 212-655-0924
[email protected]
Transfer Agent
American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
www.astfinancial.com